Stanley Bergman Sells 43,812 Shares of Henry Schein (NASDAQ:HSIC) Stock

Henry Schein, Inc. (NASDAQ:HSIC) CEO Stanley Bergman sold 43,812 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $81.31, for a total value of $3,562,353.72. Following the completion of the sale, the chief executive officer directly owned 383,803 shares of the company’s stock, valued at $31,207,021.93. The trade was a 10.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Henry Schein Stock Performance

NASDAQ HSIC opened at $80.58 on Thursday. The business’s 50 day moving average price is $78.09 and its 200-day moving average price is $72.44. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $89.29. The company has a market cap of $9.24 billion, a P/E ratio of 24.64, a P/E/G ratio of 2.37 and a beta of 0.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.34 billion. During the same period in the previous year, the firm earned $1.19 earnings per share. Henry Schein’s quarterly revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Sell-side analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Institutional Investors Weigh In On Henry Schein

Several hedge funds have recently made changes to their positions in HSIC. Reflection Asset Management bought a new stake in shares of Henry Schein in the fourth quarter valued at about $516,000. Compound Planning Inc. purchased a new position in Henry Schein during the 4th quarter valued at about $275,000. Corient Private Wealth LLC raised its holdings in shares of Henry Schein by 5.4% in the 4th quarter. Corient Private Wealth LLC now owns 37,019 shares of the company’s stock valued at $2,798,000 after purchasing an additional 1,906 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its position in shares of Henry Schein by 7.8% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,318 shares of the company’s stock worth $326,000 after purchasing an additional 312 shares during the period. Finally, State of Tennessee Department of Treasury lifted its position in shares of Henry Schein by 411.7% in the 4th quarter. State of Tennessee Department of Treasury now owns 75,773 shares of the company’s stock worth $5,719,000 after purchasing an additional 60,965 shares during the period. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Barclays initiated coverage on shares of Henry Schein in a research note on Monday, December 8th. They issued an “overweight” rating and a $86.00 price objective for the company. JPMorgan Chase & Co. raised their price target on Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Wall Street Zen raised Henry Schein from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Robert W. Baird set a $100.00 target price on Henry Schein and gave the stock an “outperform” rating in a research note on Monday, February 23rd. Finally, Morgan Stanley boosted their target price on shares of Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a research note on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.